Moving forward: biologics and biocomparables in Mexico

Biological drugs and the legislation and regulation surrounding them are topics that have provided more than one headache to governments around the world. If the fight between innovators and generic companies over non-biological medicines has always been more a matter of industrial property, when a biological medicine is involved, regulatory concerns increase the complexity of the debate.